As part of its commitment to supporting innovation as well as safety and effectiveness, the FDA has been giving artificial intelligence (AI) a lot of attention over the past few years. One topic of discussion centers on transparency and explainability: it’s important to have it, but how do you do it? And how do you do it for a wide variety of stakeholders?
A panel of legal and technical experts gathered last week for a virtual briefing on this topic as it applies to regulation and liability. Ho...
Published on June 12, 2022 17:01